Clinical Trial Update: 5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2) [Phase 3]

View source ↗

Summary

Five-year long-term follow-up from a Phase 3 pediatric trial of PegIntron plus Rebetol for chronic hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PegIntron (pegylated interferon alfa-2b)
• Rebetol (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic | Phase 3 | Status: COMPLETED | Results posted: 2013-12-17